What is Translatomics? The Missing Layer in Gene Expression

Many molecular biologists have reported that RNA-seq data show upregulation of a key gene, but protein levels do not match. Or the crucial transcriptional hits are completely absent from proteomics data, highlighting the “disconnect” between transcriptomics and proteomics data.

In this blog article, we summarise the measurable factors that affect translation, and why it is becoming increasingly important to look beyond conventional molecular methodologies to get the bigger picture. But first, let us understand the biological mechanisms that influence the translation process.

Why mRNA ≠ protein: the biology behind the “disconnect.”

Vogel and Marcotte, quoted in their 2012 article, “Current data demonstrate a substantial role for regulatory processes occurring after mRNA is made”. Many researchers have pointed out that after transcriptomics, cells undergo a decision process of what should be translated and how much.  One pan-cancer proteogenomic study has confirmed the disconnect between mRNA and protein by analyzing more than 2,555 tumor samples across 15 cancer types, revealing that the correlation coefficient between transcriptomic and proteomic measurements typically ranges from 0.3 to 0.5 [1].

This implies that researchers might be: 

• Focusing on transcriptional changes that do not lead to functional proteins

• Overlooking crucial regulatory mechanisms that operate between RNA and protein; 

• Drawing conclusions about biological processes without enough data

To understand various cellular processes and disease etiology, it has become necessary to measure the biological mechanisms that explain the correlation between mRNA abundance and protein variation. Key factors that help in decoding the disconnect are:

• Translation efficiency – Some mRNAs are translated frequently, while others remain underutilized despite being abundant. A highly abundant transcript with low translation efficiency produces far less protein than a rare transcript that's being translated intensively.
  
• Ribosome occupancy – Actively translated transcripts may be loaded with many ribosomes at once (polysomes), while repressed mRNAs usually have few or none. This explains why two transcripts with similar abundance can have different protein outputs.
  
• Translational control: Cells can reprogram translation within minutes in response to stress, signalling, or developmental cues. These rapid changes happen long before mRNA levels shift, which typically takes hours.
  
  Translation regulation thus alone exerts greater control over protein output than transcription, mRNA degradation, and protein degradation combined. Thus, molecular biologists are moving towards the “Translatomics” approach that lies between transcriptomics and proteomics. Rather than measuring what mRNAs are present, translatomics tells us which mRNAs are actually being translated into proteins at any given moment, helping explain the missing 60–70% of protein variation [1].

Decoding translatomics: from ribosomes to tRNAs

The techniques for studying translation have expanded considerably over the past decade. Each approach captures a different layer of the process, from tracking ribosome-embedded mRNA to measuring tRNA modification and decoding translation efficiency. Understanding what these tools measure and where they differ is useful for deciding which approach fits a given research question. The core methods are as follows:

Ribosome profiling (Ribo-seq) captures RNA fragments protected by actively translating ribosomes, providing a genome-wide snapshot of translation with nucleotide resolution.
Polysome profiling separates ribosomes by density on sucrose gradients, distinguishing mRNAs bound to single ribosomes from those engaged in multiple-ribosome complexes (polysomes) during active translation. 
tRNA sequencing methods quantify tRNA abundances and their chemical modification. These are crucial regulators of translation efficiency, often dysregulated in cancer and other diseases.

1. Biological decisions happen at the translation level

Many critical biological processes are primarily controlled through translation rather than transcription. The following are areas where translatomics is redefining how we see cellular processes:
A) Cancer: In cancer progression, cells exploit the translation machinery to produce proteins that promote tumour growth, even when mRNA levels remain unchanged [2,3]. Cancer cells actively rewire the translation of their mRNAs. A study by Wang et al. shows higher translation ratios in lung carcinoma cells than in normal cells using RNC-seq and Ribo-seq approaches. Moreover, Lian et al. utilised the same tools to calculate the elongation velocity index and found that the translation elongation rate of oncogenes in cancer cells decreased significantly, thereby ensuring correct folding and malignant function. Even within the tumour microenvironment, translational regulation shapes immune cell function and contributes to immune escape.

B) Neurodegenerative disease: In neurons, for example, local translation within dendrites and axons enables spatially restricted protein synthesis that supports synaptic plasticity, learning, and neuronal signalling, processes that occur far from the nucleus where transcription takes place [4,5]. Drumond-Bock et al. studied ageing mouse brain using ribosome profiling and revealed cell type-specific translational changes in dopaminergic neurons, particularly in mitochondrial and calcium signalling, that likely explain their vulnerability to neurodegeneration. Separately, Hoorn et al. applied ribosome profiling to motor neurons to identify translatome-level changes during synapse elimination that were independent of transcription, and which could be directly targeted to alter circuit development in vivo. These studies illustrate how translatomics is uncovering some of the most critical events in neural biology.

C) Cellular stress: When cells encounter environmental stressors such as heat shock, hypoxia, or nutrient deprivation, they rapidly reprogram protein production by selectively regulating translation, often within minutes, while transcriptional changes typically follow later. This rapid translational control allows cells to produce pro-survival proteins before new transcripts are produced, highlighting why studying active protein synthesis is essential for understanding cellular adaptation and disease mechanisms  [6,7].

2. Identify novel protein-coding sequences hiding in your genome

Ribosome profiling has revealed that the genome encodes far more proteins than previously recognized. By directly sequencing ribosome-protected mRNA fragments, this translatomic approach can identify genomic regions that are actively translated, even when they fall outside conventional gene annotations. Using this technology, researchers have discovered thousands of previously unannotated protein-coding sequences, including small open reading frames (smORFs) that encode functional micropeptides, upstream open reading frames (uORFs) in the 5′ untranslated regions that regulate downstream translation, and alternative reading frames that generate additional proteins from known genes [8,9]. Many smORFs encode microproteins, typically shorter than 100–150 amino acids, an emerging class of regulatory molecules involved in signaling, metabolism, and cellular stress responses [10].

Importantly, large-scale ribosome profiling and proteogenomic studies have demonstrated that ribosomes frequently occupy regions previously labeled as “non-coding,” revealing thousands of translated smORFs and novel protein-coding loci across the human genome  [9,11]. Because these peptides are often small, low-abundance, or embedded within untranslated regions, they remain largely invisible to traditional gene annotation pipelines and transcriptomics-based analyses. Translatomics, therefore, provides a powerful strategy for uncovering this hidden proteome, expanding our understanding of genome coding potential, and revealing previously unknown regulatory molecules.

3. Accelerate drug discover and development 

Translatomics is increasingly reshaping the development of RNA therapeutics and mRNA vaccines by revealing how efficiently therapeutic RNA molecules are converted into functional proteins inside cells. While the successful delivery of RNA to the target tissue is essential, the ultimate efficacy of these therapies depends on the efficient translation of the encoded sequence into the desired protein product [12]. Techniques such as ribosome profiling and other translatomic approaches enable direct measurement of the translational output of therapeutic mRNAs, providing insight into the actual protein synthesis generated from engineered constructs [13]. These methods help researchers optimize coding sequences, codon usage, and untranslated region (UTR) designs to maximize translation efficiency and stability of therapeutic transcripts [14]. Translatomics can also reveal unexpected or off-target translation products, which are critical for safety evaluation in RNA-based therapeutics. 

Beyond RNA medicines, translation profiling is also valuable in small-molecule drug discovery, particularly for compounds targeting the translation machinery or ribosome-associated pathways, where measuring changes in ribosome occupancy helps clarify drug mechanisms of action and identify translational biomarkers that predict therapeutic response  [15].

Translatomics vs. other omics: choosing the right approach

Translatomics data: how to analyze and interpret it

Translatomics data interpretation requires analytical frameworks that are purpose-built for translation biology. Different approaches produce data sets with unique characteristics that generic RNA-seq pipelines are not designed to handle. Proper analysis requires tools that can account for ribosome footprint length distributions, calculate translation efficiency, model ribosome occupancy, and integrate tRNA data alongside mRNA measurements.

Immagina’s bioinformatics Translatome Suite, Martian (mRNAs at ribosomes and tRNAs included analyzer), is a Python-based platform designed specifically for translatomic data analysis. MARTIAN was built from the ground up for translatome analysis, incorporating best practices specific to ribosome footprint data. MARTIAN guides researchers from raw sequencing reads through quality control, alignment, quantification, translation-efficiency calculation, ribosome-occupancy modeling, statistical analysis, visualization, and functional interpretation.

Learn more about MARTIAN

The Future of Translatomics

The coming years are likely to reshape how translation is studied. Over the past decade, ribosome profiling has revealed the dynamic nature of translation across genomes, but the next generation of technologies is poised to extend these insights with far greater spatial, cellular, and analytical resolution.

One of the most exciting frontiers is single-cell translatomics, measuring ribosome engagement at single-cell resolution. This can help in understanding cancer, developmental biology, and immunology, where cellular states change rapidly in response to environmental cues  [16].

Similarly, the integration of spatial transcriptomics with translation analysis is beginning to illuminate where protein synthesis occurs within intact tissues. This can allow researchers to map RNA localization across tissue architecture, and combining these approaches with measurements of active translation provides a deeper understanding of how cells regulate protein production in context Sui et al., (2025).

Together, these technological and computational innovations are pushing translatomics beyond basic research and toward clinical and translational applications. By directly measuring protein synthesis rather than inferring it from RNA abundance, translatomics offers a powerful new dimension for biomarker discovery, therapeutic target identification, and precision medicine, revealing functional regulatory processes that remain invisible to DNA- or RNA-based profiling alone [2,3].

Ready to see what your transcriptomics data isn't telling you? Future of Translatomics

Immagina Biotech's translatomics platform ranges from gel-free ribosome profiling to sequencing of native tRNAs to protein detection and analysis. Learn more about our technologies:

• RiboLace: Gel-free active ribosome profiling requires a minimum starting material of just 35,000 cells, depending on the specimen type, translational activity, and type of experiment.
• nano-tRNAseq: tRNA sequencing with simultaneous detection of tRNA abundance and chemical modifications
• MARTIAN: Dedicated bioinformatics suite for translatome analysis
• DOORs: Detection of 3'-phosphorylated RNA fragments for novel biomarker discovery

Take the next step

Explore Our Technologies – Learn how our platform enables translatomics research

Browse Applications – See how translatomics is advancing disease research

Talk to Our Experts – Discuss how translatomics can advance your research

Immagina Biotechnology pioneers RNA and ribosome-focused technologies that decode translational landscapes. Our platform supports biotech, pharmaceutical R&D, and academic researchers working on disease mechanisms, drug discovery, and biomarker development. All products are for Research Use Only (RUO).

References and further reading

1. Liu, Y., Beyer, A., & Aebersold, R. (2016). On the dependency of cellular protein levels on mRNA abundance. Cell, 165(3), 535-550.
2. Ruggero, D. (2013). Translational control in cancer etiology. Cold Spring Harbor perspectives in biology, 5(2), a012336..
3. Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015). Targeting the translation machinery in cancer. Nature reviews Drug discovery, 14(4), 261-278.
4. Holt, C. E., & Schuman, E. M. (2013). The central dogma decentralized: new perspectives on RNA function and local translation in neurons. Neuron, 80(3), 648-657.
5. Biever, A., Glock, C., Tushev, G., Ciirdaeva, E., Dalmay, T., Langer, J. D., & Schuman, E. M. (2020). Monosomes actively translate synaptic mRNAs in neuronal processes. Science, 367(6477), eaay4991..
6. Spriggs, K. A., Bushell, M., & Willis, A. E. (2010). Translational regulation of gene expression during conditions of cell stress. Molecular cell, 40(2), 228-237..
7. Liu, B., & Qian, S. B. (2014). Translational reprogramming in cellular stress response. Wiley Interdisciplinary Reviews: RNA, 5(3), 301-305..
8. Chothani, S., Ho, L., Schafer, S., & Rackham, O. (2023). Discovering microproteins: making the most of ribosome profiling data. RNA biology, 20(1), 943-954..
9. Tong, G., & Martinez, T. F. (2025). Ribosome profiling reveals hidden world of small proteins. Trends in Genetics, 41(2), 101-103..
10. Cao, K., Heydary, Y. H., Tong, G., & Martinez, T. F. (2023). Integrated workflow for discovery of microprotein-coding small open reading frames. STAR protocols, 4(4)..
11. Kore, H., Okano, S., Datta, K. K., Thorp, J., Periasamy, P., Divate, M., ... & Gowda, H. (2025). Identification of Small Open Reading Frame-encoded Proteins in the Human Genome. Genomics, Proteomics & Bioinformatics, 23(1), qzaf004..
12. Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery, 17(4), 261-279..
13. Ingolia, N. T., Ghaemmaghami, S., Newman, J. R., & Weissman, J. S. (2009). Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. science, 324(5924), 218-223..
14. Leppek, K., Das, R., & Barna, M. (2018). Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them. Nature Reviews Molecular Cell Biology, 19(3), 158-174.
15. Shichino, Yuichi, and Shintaro Iwasaki. "Compounds for selective translational inhibition." Current Opinion in Chemical Biology 69 (2022): 102158.
16. Brar, G. A., & Weissman, J. S. (2015). Ribosome profiling reveals the what, when, where, and how of protein synthesis. Nature Reviews Molecular Cell Biology, 16(11), 651-664.